Amended Statement of Ownership (sc 13g/a)
17 Dicembre 2020 - 12:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment
No. 1)
Lixte
Biotechnology Holdings, Inc.
(Name
of Issuer)
Common
Stock, $0.0001 par value per share
(Title
of Class of Securities)
539319
2029(Common Stock)
539319-11
(Public Warrants)
(CUSIP
Number)
November
30, 2020
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]
Rule 13d-1(b)
[X]
Rule 13d-1(c)
[ ]
Rule 13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall not be subject to all other provisions of the Act (however, see the Notes).
CUSIP
NO. 539319 10 3
|
Page
2 of 5 Pages
|
1.
|
NAMES OF REPORTING PERSONS.
|
|
Hung Tak Ho
|
|
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a) [ ]
|
|
(b) [X]
|
|
|
3.
|
SEC USE ONLY
|
|
|
4.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
United Kingdom
|
|
|
|
|
NUMBER OF
|
5.
|
SOLE VOTING POWER
|
1,084,210(1)
|
SHARES
|
|
|
|
BENEFICIALLY
|
6.
|
SHARED VOTING POWER
|
0
|
OWNED BY
|
|
|
|
EACH
|
7.
|
SOLE DISPOSITIVE POWER
|
1,084,210(1)
|
REPORTING
|
|
|
|
PERSON WITH
|
8.
|
SHARED DISPOSITIVE POWER
|
0
|
9.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON.
|
|
1,084,210(1)
|
|
|
10.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
|
|
CERTAIN SHARES
|
[ ]
|
|
|
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)(2)
|
|
8.73%
|
|
|
12.
|
TYPE OF REPORTING PERSON
|
|
|
|
IN
|
2
|
Consists
of (a) 1,042,105 shares of Common Stock and (b)a Warrant to purchase 42,105 shares of
Common Stock
|
|
|
3
|
Based
on 12,374,302 shares of common stock outstanding as of November 30, 2020.
|
CUSIP
NO. 539319 10 3
|
Page
3 of 5 Pages
|
Item
1(a). Name of Issuer.
The
name of the issuer is Lixte Biotechnology Holdings, Inc. (the “Issuer”).
Item
1(b). Address of Issuer’s Principal Executive Offices.
The
address of the Issuer’s principal executive office is 248 Route 25A, No. 2, East Setauket, New York 11733.
Item
2(a). Name of Person Filing.
The
name of the person filing is Hung Tak Ho (the “Reporting Person”).
Item
2(b). Address of Principal Business Office, or, if None, Residence.
The
address of the Reporting Person is Mayfair By The Sea II, Tower T8, 1/F, Unit A, 21 Fo Chun Road, Taipo NT, Hong Kong SAR.
Item
2(c). Citizenship.
The
Reporting Persons is a citizen of the United Kingdom.
Item
2(d). Title of Class of Securities.
The
title of the class of securities to which this statement relates is the common stock of the Issuer, $0.0001 par value per share
(the “Common Stock”).
Item
2(e). CUSIP No.
The
CUSIP number is 539319-202 (Common Stock) and 539319-11 (Public Warrants).
Item
3. If This Statement is Filed Pursuant to Rule 13d-1(b) or 13d-2(b), Check Whether the Person Filing is a:
(a)
|
[ ]
|
Broker
or dealer registered under Section 15 of the Act
|
(b)
|
[ ]
|
Bank
as defined in Section 3(a)(6) of the Act
|
(c)
|
[ ]
|
Insurance
Company as defined in Section 3(a)(19) of the Act
|
(d)
|
[ ]
|
Investment
Company registered under Section 8 of the Investment Company Act of 1940
|
(e)
|
[ ]
|
Investment
Adviser registered under section 203 of the Investment Advisers Act of 1940
|
(f)
|
[ ]
|
Employee
Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment
Fund; see Rule 13d-1(b)(1)(ii)(F)
|
(g)
|
[ ]
|
Parent
Holding Company, in accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See Item 7)
|
(h)
|
[ ]
|
Group,
in accordance with Rule 13d-1(b)(1)(ii)(H).
|
Item
4. Ownership.
The
information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page and is incorporated herein
by reference.
CUSIP
NO. 539319 10 3
|
Page
4 of 5 Pages
|
Item
5. Ownership of Five Percent or Less of a Class.
Not
applicable.
Item
6. Ownership of More than Five Percent on Behalf of Another Person.
Not
Applicable.
Item
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
Not
Applicable.
Item
8. Identification and Classification of Members of the Group.
Not
Applicable.
Item
9. Notice of Dissolution of Group.
Not
Applicable.
Item
10. Certifications.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
CUSIP
NO. 539319 10 3
|
Page5
of 5 Pages
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
Dated:
December 15, 2020
|
|
|
|
/s/
HUNG TAK HO
|
|
Hung
Tak Ho
|
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024